🇪🇺 NVX-108 in European Union

EMA authorised NVX-108 on 17 July 1998

Marketing authorisation

EMA — authorised 17 July 1998

  • Application: EMEA/H/C/000149
  • Marketing authorisation holder: Sonus Pharmaceuticals Ltd.
  • Local brand name: EchoGen
  • Indication: EchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation. EchoGen should only be used in patients where the study without contrast enhancement is inconclusive.
  • Status: withdrawn

Read official source →

Frequently asked questions

Is NVX-108 approved in European Union?

Yes. EMA authorised it on 17 July 1998.

Who is the marketing authorisation holder for NVX-108 in European Union?

Sonus Pharmaceuticals Ltd. holds the EU marketing authorisation.